Global Brain Tumor Diagnosis and Treatment Industry New

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
64
Global Brain Tumor Diagnosis and Treatment Industry

New York, Sept. 19, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Brain Tumor Diagnosis and Treatment Industry" - https://www.reportlinker.com/p05960584/?utm_source=GNW 5 Million by 2027, growing at aCAGR of 7.4% over the period 2020-2027. Primary Brain Tumor, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$587.1 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Secondary Brain Tumor segment is readjusted to a revised 7.9% CAGR for the next 7-year period. The U.S. Market is Estimated at $145.3 Million, While China is Forecast to Grow at 11.2% CAGR The Brain Tumor Diagnosis and Treatment market in the U.S. is estimated at US$145.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$197 Million by the year 2027 trailing a CAGR of 11.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 6.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.We bring years of research experience to this 7th edition of our report. The 381-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others,

  • AstraZeneca PLC
  • Carestream Health, Inc.
  • GE Healthcare
  • Hitachi Medical Corporation
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Philips Healthcare
  • Shimadzu Corporation
  • Siemens Healthineers
  • Toshiba Medical Systems Corporation

Read the full report: https://www.reportlinker.com/p05960584/?utm_source=GNW I. INTRODUCTION, METHODOLOGY & REPORT SCOPE II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Global Competitor Market Shares Brain Tumor Diagnosis and Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 2: World Historic Review for Brain Tumor Diagnosis and Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 3: World 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Primary Brain Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 5: World Historic Review for Primary Brain Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 6: World 15-Year Perspective for Primary Brain Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Secondary Brain Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 8: World Historic Review for Secondary Brain Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 9: World 15-Year Perspective for Secondary Brain Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 11: World Historic Review for CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 12: World 15-Year Perspective for CT Scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for MRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 14: World Historic Review for MRI by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 15: World 15-Year Perspective for MRI by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for PET-CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 17: World Historic Review for PET-CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 18: World 15-Year Perspective for PET-CT Scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 19: World Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 20: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 21: World 15-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 22: World Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 23: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 24: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 25: World Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 26: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 27: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 28: World Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 29: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 30: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 31: World Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 32: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 33: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 34: World Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 35: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 36: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Facts & Figures US Brain Tumor Diagnosis and Treatment Market Share (in %) by Company: 2019 & 2025 Market Analytics Table 37: USA Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 38: USA Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 39: USA 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 40: USA Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 41: USA Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 42: USA 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 43: USA Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 44: USA Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 45: USA 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 CANADA Table 46: Canada Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 47: Canada Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 48: Canada 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 49: Canada Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 50: Canada Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 51: Canada 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 52: Canada Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 53: Canada Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 54: Canada 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 JAPAN Table 55: Japan Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 56: Japan Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 57: Japan 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 58: Japan Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 59: Japan Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 60: Japan 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 61: Japan Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 62: Japan Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 63: Japan 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 CHINA Table 64: China Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 65: China Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 66: China 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 67: China Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 68: China Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 69: China 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 70: China Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 71: China Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 72: China 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures European Brain Tumor Diagnosis and Treatment Market: Competitor Market Share Scenario (in %) for 2019 & 2025 Market Analytics Table 73: Europe Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 Table 74: Europe Historic Review for Brain Tumor Diagnosis and Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 75: Europe 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 76: Europe Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 77: Europe Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 78: Europe 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 79: Europe Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 80: Europe Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 81: Europe 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 82: Europe Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 83: Europe Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 84: Europe 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 FRANCE Table 85: France Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 86: France Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 87: France 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 88: France Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 89: France Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 90: France 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 91: France Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 92: France Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 93: France 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 GERMANY Table 94: Germany Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 95: Germany Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 96: Germany 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 97: Germany Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 98: Germany Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 99: Germany 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 100: Germany Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 101: Germany Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 102: Germany 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 ITALY Table 103: Italy Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 104: Italy Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 105: Italy 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 106: Italy Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 107: Italy Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 108: Italy 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 109: Italy Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 110: Italy Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 111: Italy 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 112: UK Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 113: UK Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 114: UK 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 115: UK Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 116: UK Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 117: UK 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 118: UK Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 119: UK Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 120: UK 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Treatment Type - Percentage Breakdown of Value Sales for Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy for the Years 2012, 2020 & 2027 SPAIN Table 121: Spain Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 122: Spain Historic Review for Brain Tumor Diagnosis and Treatment by Type - Primary Brain Tumor and Secondary Brain Tumor Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 123: Spain 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Type - Percentage Breakdown of Value Sales for Primary Brain Tumor and Secondary Brain Tumor for the Years 2012, 2020 & 2027 Table 124: Spain Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 125: Spain Historic Review for Brain Tumor Diagnosis and Treatment by Diagnosis Type - CT Scan, MRI, PET-CT Scan and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Table 126: Spain 15-Year Perspective for Brain Tumor Diagnosis and Treatment by Diagnosis Type - Percentage Breakdown of Value Sales for CT Scan, MRI, PET-CT Scan and Other Diagnosis Types for the Years 2012, 2020 & 2027 Table 127: Spain Current & Future Analysis for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 Table 128: Spain Historic Review for Brain Tumor Diagnosis and Treatment by Treatment Type - Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 Please contact our Customer Support Center to get the complete Table of Contents Read the full report: https://www.reportlinker.com/p05960584/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________

Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's Manufacturing: Squeeze or Opportunity?

Updated Category News Views 1

Analyzing China's Impact on Global Markets Think of China's manufacturing clout and you're likely to picture booming factories, relentless steel, and smoke-churning industries reshaping the global chessboard. But here's the kicker: are they swallowing up room for others, or paving the way for their growth? It’s this debate that took the spotlight at the Asia-Pacific...

Continue Reading
Pudu D7 Robot Shines at IFA, Setting New Robotics Bar

Updated Category News Views 2

Breaking New Ground in Robotics at IFA Well, here's a nugget for robotics buffs and investors alike: Pudu Robotics, a heavyweight in commercial service robotics, is carving out a fresh chapter with its PUDU D7. Making waves as an honoree at the IFA Innovation Awards, the D7 presents a mash-up of brains and brawn—exemplifying the future path for robotics. The PUDU D7...

Continue Reading
Changhong's IFA 2026 Showcase: AI, Culture & Localization

Updated Category News Views 3

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

Continue Reading
Morpho Unveils Versatile UV Printer at IFA 2026

Updated Category News Views 4

IFA 2026: A New Frontier for Desktop Printing You've seen your fair share of printers over the years, but when a company like Morpho steps onto the scene with a gadget that echoes innovation, it makes you perk up those market-ears. We're talking the big unveil of their desktop UV printer at the IFA 2026 in Berlin. Morpho's contraption isn't just spewing out ink; it's...

Continue Reading
York Space Systems Faces Class Action Over Misleading IPO

Updated Category News Views 2

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

Continue Reading
Roborock Fuels Market Surge with 27.6% Revenue Boost

Updated Category News Views 1

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Continue Reading
Hims & Hers Faces Class Action: Investors Beware

Updated Category News Views 1

Allegations and Legal Pressure There's trouble brewing in the land of health and wellness apps, with Hims & Hers Health, Inc. (NYSE:HIMS) taking center stage. Slap on your glasses, folks, because this one's a doozy. A class-action lawsuit has exploded against the company and some of its officers—allegations flying as they focus on serious accusations of misleading...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 1

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
LiberNovo Demos Ergonomic Seating at IFA 2026

Updated Category News Views 3

Riding the Ergonomic Wave at IFA 2026 No stranger to the innovation spotlight, LiberNovo’s got its eyes on Berlin this time around. As sparks fly at the IFA 2026, they’re rolling out their grand Maxis Series and rubbing shoulders with big names in technology. How does a company shake things up in a sea of tech? Start by thinking big and tall—literally. Maxis Series:...

Continue Reading
See's Candies Data Breach Spurs Legal Scrutiny

Updated Category News Views 12

Data Breach Hits See's Candies Hard Amidst Ransomware Attack Alright, folks, here's a not-so-sweet tale to kick off your day — See's Candies has found itself in a bit of a pickle. A ransomware attack, the nasty kind that makes you double-check your locks and your passwords, has reportedly exposed the personal data of its customers and employees. We're talking names,...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Recent Viatris Investigation and Its Impact

Updated Category News Views 285

Investigating the Viatris Landscape Recently, concerns have arisen regarding Viatris Inc. and the challenges it faces as a publicly traded company. The legal firm Faruqi & Faruqi, LLP has taken the initiative to investigate potential claims on behalf of investors, specifically focusing on those who may have suffered considerable losses in Viatris stock. Company Background...

Continue Reading
Horizon Robotics Partners with Bosch for Enhanced Driving Safety

Updated Category News Views 319

Horizon Robotics and Bosch Strengthen Partnership for Advanced Driving Solutions Horizon Robotics, known for its innovative smart driving technologies, and Bosch, a global leader in automotive components and services, have joined forces in a strategic collaboration to develop cutting-edge assisted driving solutions for a variety of automakers. This joint effort is aimed...

Continue Reading
CareCloud's Thriving Q3 2025: Growth with Strategic Moves

Updated Category News Views 110

CareCloud's Strong Q3 Performance Overview CareCloud, Inc. (NASDAQ: CCLD, CCLDO) has recently reported remarkable financial results for the third quarter of 2025, reflecting a period of significant growth and strategic development. The company has raised its revenue guidance for the full year to an impressive $117 to $119 million, improving from the previously estimated...

Continue Reading
Constellation Brands Announces Update on Financial Reporting Dates

Updated Category News Views 242

Update on Financial Reporting Dates Constellation Brands, Inc. (NYSE: STZ), a prominent player in the beverage alcohol space, has announced an important update regarding the timing of its financial results for the second quarter. Originally scheduled earlier, the new reporting date is set for October 6, 2025, after the U.S. markets close. Investors and those interested...

Continue Reading
NB Private Equity Partners Declares 2H 2025 Dividend Payment

Updated Category News Views 147

NB Private Equity Partners Announces 2H 2025 Dividend NB Private Equity Partners (“NBPE”), a prominent private equity investment company, has revealed the details for its upcoming dividend, reaffirming its commitment to generating value for shareholders. Details of the 2H 2025 Dividend In a move that underscores its robust market performance, NBPE will distribute a...

Continue Reading